Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy
NCT ID: NCT02072408
Last Updated: 2018-09-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
46 participants
INTERVENTIONAL
2014-02-28
2017-11-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
NCT01950741
Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)
NCT02860858
Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept
NCT04707027
Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
NCT00383812
Real Life Study in Myopic Neovascularization
NCT03797547
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
polypoidal choroidal vasculopathy without polyp
aflibercept
1. Three monthly intravitreal aflibercept (2mg) injections
2. Five bimonthly intravitreal aflibercept (2mg) injections
3. Rescue treatment: Verteporfin photodynamic therapy
* Loss of five ETDRS letters or one Snellen line of vision from baseline
* Presence of subretinal fluid or intraretinal fluid despite three consecutive (monthly or bimonthly) aflibercept injection
* Presence of active polyp on indocyanine green angiography
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
aflibercept
1. Three monthly intravitreal aflibercept (2mg) injections
2. Five bimonthly intravitreal aflibercept (2mg) injections
3. Rescue treatment: Verteporfin photodynamic therapy
* Loss of five ETDRS letters or one Snellen line of vision from baseline
* Presence of subretinal fluid or intraretinal fluid despite three consecutive (monthly or bimonthly) aflibercept injection
* Presence of active polyp on indocyanine green angiography
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* decreased visual acuity by subretinal fluid and hemorrhage involving foveal center
Exclusion Criteria
* previous photodynamic therapy more than three times
* anti-VEGF injection within one month
* photodynamic therapy or intraocular steroid treatment within three months
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Bundang Hospital
OTHER
Kim's Eye Hospital
OTHER
Bayer
INDUSTRY
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Bundang Hospital
Seongnam, Gyunggi-do, South Korea
Konyang University Kim's Eye Hospital
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-10-044-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.